Merck & Co., Inc. (NYSE:MRK) Shares Bought by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 452.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 138,649 shares of the company’s stock after acquiring an additional 113,541 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Merck & Co., Inc. were worth $10,425,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. PARK CIRCLE Co grew its stake in shares of Merck & Co., Inc. by 100.0% during the second quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock valued at $31,000 after acquiring an additional 200 shares in the last quarter. Macroview Investment Management LLC grew its stake in Merck & Co., Inc. by 47.4% in the third quarter. Macroview Investment Management LLC now owns 426 shares of the company’s stock worth $32,000 after purchasing an additional 137 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in Merck & Co., Inc. in the second quarter worth about $37,000. Monumental Financial Group Inc. acquired a new position in Merck & Co., Inc. in the second quarter worth about $44,000. Finally, Strategic Asset Management LLC acquired a new position in Merck & Co., Inc. in the third quarter worth about $44,000. Institutional investors own 71.43% of the company’s stock.

MRK opened at $81.15 on Friday. The business’s 50 day moving average is $78.27 and its 200-day moving average is $77.98. The stock has a market cap of $204.98 billion, a PE ratio of 28.63, a price-to-earnings-growth ratio of 1.78 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 1.07 and a debt-to-equity ratio of 0.64. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $91.40.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, October 27th. The company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.55 by $0.20. The company had revenue of $13.15 billion for the quarter, compared to analysts’ expectations of $12.32 billion. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.74 earnings per share. As a group, analysts forecast that Merck & Co., Inc. will post 5.8 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, January 7th. Investors of record on Wednesday, December 15th were issued a dividend of $0.69 per share. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.65. The ex-dividend date was Tuesday, December 14th. This represents a $2.76 annualized dividend and a yield of 3.40%. Merck & Co., Inc.’s payout ratio is presently 97.53%.

MRK has been the subject of a number of research reports. SVB Leerink reiterated a “buy” rating on shares of Merck & Co., Inc. in a research note on Tuesday, November 30th. The Goldman Sachs Group initiated coverage on Merck & Co., Inc. in a research note on Friday, December 17th. They issued a “conviction-buy” rating and a $93.00 price target for the company. Truist Securities lifted their price target on Merck & Co., Inc. from $92.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, November 24th. Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $88.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, November 29th. Finally, Barclays raised their target price on shares of Merck & Co., Inc. from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Monday, November 1st. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $91.65.

In related news, EVP Frank Clyburn sold 39,762 shares of the business’s stock in a transaction that occurred on Monday, November 1st. The stock was sold at an average price of $87.87, for a total transaction of $3,493,886.94. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kenneth C. Frazier sold 663,881 shares of the business’s stock in a transaction that occurred on Tuesday, November 9th. The stock was sold at an average price of $82.26, for a total value of $54,610,851.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 936,784 shares of company stock worth $78,682,559. 0.32% of the stock is owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More: Profit Margin

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.